Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable ...

In an opinion article, investigators argue that gene therapies may not achieve their full potential if the innate inflammation in Duchenne muscular dystrophy is not effectively managed.

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

In a conversation with Managed Healthcare Executive, Michael Abrams, M.A., managing partner at Numerof & Associates, painted ...

While the impact of Medicaid changes on employer-sponsored insurance remains to be seen, competition between providers is a ...

After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

Climate change and air pollution are growing threats to public health, and new research suggests they may also worsen atopic ...

Care gaps in women’s health are closing, thanks to increased cultural awareness of gendered healthcare disparities, according ...

Absent a federal committee’s recommendation, Duchenne muscular dystrophy advocates are trying to get states to adopt ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Employers, some lawmakers and others have criticized pharmacy benefit managers (PBMs), especially the "big three," for having ...